Loading stock data…
$22.07-0.24 (-1.10%)
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Structure Therapeutics Inc. in the Healthcare sector is trading at $22.07 with a market capitalization of $2.7B. Wall Street consensus targets $105.78 (15 analysts), implying a +379.4% move over the next 12 months. The stock is currently near its 52-week low of $22.00, remaining 57.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 0 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$118.63M↓ | -$89.38M↓ | $13.74M↑ | -$73.79M↓ | -$70.45M |
| Net Income | -$106.16M↓ | -$75.97M↓ | $33.00M↑ | -$65.71M↓ | -$61.66M |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate i...